Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Zymeworks Inc.NASDAQ: ZYME
Gross Profit · Q3 FY2026 · quarter ended Sep 2026
Gross profit growth accelerates
Q3 FY2026 gross profit of $177.6M rose 543.1% year over year, ahead of the +35.8% change in trailing-twelve-month gross profit. Sequentially, it rose 3769.2% from the prior quarter. Over 3 fiscal years it compounded at -36.4% a year.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, unchanged from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +543.1% holds above the trailing-twelve-month pace of +35.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 105.97M USD
- Year-over-year change
- +38.9%
- 4-year CAGR
- +41.2%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 105.97M | +38.9% |
| FY2024 | 2024-12-31 | 76.3M | +213.9% |
| FY2023 | 2023-12-31 | (66.98M) | -116.2% |
| FY2022 | 2022-12-31 | 412.48M | +1446.0% |
| FY2021 | 2021-12-31 | 26.68M | — |
Gross Profit vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 gross profit of $182.57M is the 2nd highest of the 11 companies compared; the peer median is $40.38M.
- Its year-over-year change of +35.8% is the 5th highest of 10, against a peer median of +31.8%.
- Gross profit amounts to 68.6% of revenue for ZYME, versus a peer median of 89.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $607.18M | +545.5% | — | 86.5% | |
| LTM Sep 2026 | $182.57M | +35.8% | -36.4% | 68.6% | |
| LTM Mar 2026 | $109.85M | +16.2% | -9.3% | 69.9% | |
| LTM Mar 2026 | $71.82M | +2.1% | -29.1% | 90.7% | |
| LTM Mar 2026 | $63.98M | +230.5% | +113.5% | 88.1% | |
| LTM Jun 2026 | $45.46M | -54.8% | — | 43.3% | |
| LTM Mar 2026 | $35.29M | -76.1% | +12.8% | 99.3% | |
| LTM Mar 2026 | $11.88M | — | +424.9% | 100.0% | |
| LTM Mar 2026 | -$150K | +31.8% | — | — | |
| LTM Sep 2026 | -$742K | +99.6% | — | 662.5% | |
| LTM Sep 2026 | -$753K | +98.1% | — | — | |
| Peer median (excluding ZYME) | $40.38M | +31.8% | +12.8% | 89.4% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.